Pune-based Emcure Pharmaceuticals has pulled out its proposed red herring prospectus or DRHP with securities market regulator SEBI. Emcure Pharmaceuticals on Wednesday said it has filed a draft red herring prospectus (DRHP) with the Sebi for launching an initial public offer. Pune-based Emcure Pharmaceuticals has filed draft red herring prospectus ( DRHP) with SEBI for initial public offering that includes fresh issue.
|Published (Last):||13 February 2008|
|PDF File Size:||9.67 Mb|
|ePub File Size:||3.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
Pune-based Emcure Pharmaceuticals has pulled out its proposed initial public offer IPO which was to raise around Rs crore besides giving part exit to Blackstone in its maiden investment in India.
Emcure Pharmaceuticals files IPO papers with SEBI
Get instant notifications from Economic Times Allow Not now You can switch off notifications anytime using browser settings. Blackstone has invested Rs crore in Emcure through convertible shares and currently holds a To see your saved stories, click on link hightlighted in bold.
Reliance to buy majority stake in renewable energy services firm Kanoda. Emcure was the first private equity investment by a Blackstone-managed fund in India. Navy divers re-enter shaft, want water level reduced New Year eve: Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. From Berlin to Emcrue Bain Capital has paid nearly Rs. Another pharmaceutical firm which filed for public offering recently was Intas Pharmaceuticals.
Emcure Pharmaceuticals withdraws proposed IPO. Crude oil prices to direct sugar prices in It is ranked much higher in the therapeutic areas in which it operates. The PE firm is selling around 1. Mandhana added that while an IPO is a convenient route for exits, secondary transactions provide more comfort to the new investor as potential corporate governance issues emcurf have already been taken care of by the exiting PE firm.
emcuee These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients. Deepti Chaudhary Malvika Joshi. We have not given a thought to a pre-IPO funding round. The pharma company intends to utilise the net proceeds for setting up of new manufacturing facilities and expansion of emcurw manufacturing facilities; research and development; and general corporate purposes.
British support-services provider Serco Group Plc. NIFTY 50 10, 2. Drag according to your convenience. Choose your reason below and click on the Report button.
Private equity major Blackstone has started the process of exiting its maiden investment in India, Emcure Pharmaceuticals. Promoter Satish Ramanlal Mehta holds The IPO comprises a fresh issue of equity shares aggregating up to Fmcure crore and an offer for sale of up emcyre 2, equity shares by certain existing shareholders of the company, a statement issued here said.
Emcure is ranked among the top 15 pharmaceutical companies in India in terms of market share based on the domestic sales of pharmaceutical products. The firm is now evaluating options for an offshore listing.
Blackstone to sell its stake in Emcure to Bain
Infibeam calls off pact to acquire Snapdeal unit Unicommerce. Never miss a great news story! Here’s how the world is celebrating Christmas. Book drbp lead managers to the issue include Bank of America Merrill Lynch.
Blackstone to sell its stake in Emcure to Bain – Livemint
For the nine months ended December 31,Emcure’s revenue from operations was Rs 1, crore with net profit at Rs Sensex finishes year above 36, posts third straight annual gain. Leave Your Comment s. These areas include cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients. Emcure operates emcre manufacturing facilities, eight of which are located in India and one in the United States.
Blackstone has exited now. Ltd with returns of almost three times. Jul 03, Antibiotics made by Emcure Pharmaceuticals recalled in US.
Emcure is ranked as the 14th-largest pharmaceutical company in India in terms of market share based on the domestic sales of pharmaceutical emcrue. Find this comment offensive? This follows a deal struck late last year where Blackstone sold its stake to Bain Capital for an undisclosed amount. Emcure is ranked the 14th largest pharmaceutical company in India in terms of market emcute based on the domestic sales of pharmaceutical products, according to healthcare services information provider IMS Health India.